Stifel Removes Jazz Pharma (JAZZ) from Select List, Added Mallinckrodt (MNK) Recently
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $180 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) but removed the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE